Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

12,795 total articles

Palvella Therapeutics Strengthens QTORIN™ Pitavastatin Intellectual Property with Yale-Licensed U.S. Patent Providing Protection into 2043

Palvella Therapeutics Strengthens QTORIN™ Pitavastatin Intellectual Property with Yale-Licensed U.S. Patent Providing Protection into 2043

Palvella Therapeutics announced the issuance of a U.S. patent licensed from Yale University that strengthens intellectual property protection for its QTORIN™ pitavastatin program targeting porokeratosis, including disseminated superficial actinic porokeratosis (DSAP). This patent provides broad protection into 2043 for topical mevalonate pathway in…

Quantum Cyber Files Provisional Patent Application for Coaxial Dual-Propellant Grain Solid Rocket Motor Designed to Extend Range and Loiter Time of Defense UAVs

Quantum Cyber Files Provisional Patent Application for Coaxial Dual-Propellant Grain Solid Rocket Motor Designed to Extend Range and Loiter Time of Defense UAVs

Quantum Cyber N.V., a Nasdaq-listed autonomous defense technology company, announced filing a provisional patent application for a Coaxial Dual-Propellant Grain Solid Rocket Motor (CDPG-SRM). The technology aims to extend range and endurance for small unmanned aerial vehicles used in defense, border security, and autonomous warfare, addressing key …

Invivyd to Participate in Upcoming Investor Events

Invivyd to Participate in Upcoming Investor Events

Invivyd, Inc., a U.S.-based biopharmaceutical company specializing in antibody treatments for viral infectious diseases, announced it will participate in several investor events in June 2026, including the Jefferies Global Healthcare Conference, H.C. Wainwright Virtual Fireside Chat, and BTIG Infectious Disease Day. The company highlights its propr…

Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026

Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026

Atea Pharmaceuticals announced Phase 1 data indicating their fixed-dose combination regimen of bemnifosbuvir and ruzasvir (BEM/RZR) for hepatitis C virus (HCV) treatment displays a low risk of drug-drug interactions, supporting its use alongside common medications such as omeprazole and rosuvastatin. Additionally, preclinical results for AT-587, a …

Dycom Industries, Inc. Reports Record First Quarter Results and Raises Full Year Fiscal 2027 Outlook

Dycom Industries, Inc. Reports Record First Quarter Results and Raises Full Year Fiscal 2027 Outlook

Dycom Industries, Inc. reported record first quarter fiscal 2027 results with contract revenues of $1.965 billion, a 56.1% increase from the prior year, strong profitability, and a backlog growth of 46.5%. The company raised its full-year fiscal 2027 outlook and announced the acquisition of National Technology Integrators to enhance its Building Sy…

BrewDog Turns This Summer’s Global Football Tournament into a Nationwide Celebration of Beer, Bars and Big Match Moments

BrewDog Turns This Summer’s Global Football Tournament into a Nationwide Celebration of Beer, Bars and Big Match Moments

BrewDog, a leading UK craft beer brand owned by Tilray Brands, is launching a nationwide summer campaign called 'Underdog' to coincide with the global football tournament. The campaign includes a 'Win a Year of Beer' promotion across major UK retailers, in-bar football watch parties, themed events, and extensive digital and retail activations. This…

Satellos to Participate in Upcoming Investor Conferences

Satellos to Participate in Upcoming Investor Conferences

Satellos Bioscience Inc., a clinical-stage biotech focused on developing treatments for degenerative muscle diseases, will participate in upcoming investor conferences in June 2026. The company will present updates on its lead drug candidate, SAT-3247, currently in Phase II trials for Duchenne muscular dystrophy (DMD). SAT-3247 targets the AAK1 pro…

Sagimet Biosciences Presents Two Posters at EASL 2026 on Denifanstat/Resmetirom Combination in MASH

Sagimet Biosciences Presents Two Posters at EASL 2026 on Denifanstat/Resmetirom Combination in MASH

Sagimet Biosciences announced the presentation of two posters at EASL 2026 showcasing Phase 1 clinical data on the combination of denifanstat and resmetirom for treatment of metabolic dysfunction-associated steatohepatitis (MASH). The combination was generally well-tolerated and demonstrated rapid reductions in total and LDL cholesterol, suggesting…

Aurora Mobile's GPTBots.ai Upgrades AI Agents from Chat to Execution

Aurora Mobile's GPTBots.ai Upgrades AI Agents from Chat to Execution

Aurora Mobile Limited announced major upgrades to its enterprise AI platform GPTBots.ai, enhancing its capabilities from conversational AI to active execution within business workflows. Key improvements include a knowledge graph-based understanding system, advanced multi-agent workflow execution, and strengthened governance for secure production de…

Rocket Lab Achieves Milestone for Missile Defense Constellation, Passes System Requirements Review for SDA Tracking Layer Tranche 3

Rocket Lab Achieves Milestone for Missile Defense Constellation, Passes System Requirements Review for SDA Tracking Layer Tranche 3

Rocket Lab USA, Inc. has successfully passed the System Requirements Review for the Space Development Agency's Tracking Layer Tranche 3 constellation, confirming their proposed solution meets operational requirements for missile warning and defense satellites. This milestone supports a contract valued at approximately $816 million, adding to Rocket…

Climb Announces North American Distribution Partnership with Quantum

Climb Announces North American Distribution Partnership with Quantum

Climb Global Solutions, an international specialty technology distributor, announced a new North American distribution partnership with Quantum Corporation, a leader in data protection and management solutions. This partnership expands access to Quantum's product portfolio, helping resellers address complex data challenges with high-performance sto…

G-III Apparel Group Declares Quarterly Dividend

G-III Apparel Group Declares Quarterly Dividend

G-III Apparel Group, Ltd., a global fashion leader with a diverse brand portfolio, declared a quarterly cash dividend of $0.10 per share payable to shareholders on July 8, 2026. The announcement reflects the company's ongoing commitment to returning value to investors amid its extensive licensing and retail operations in the fashion sector.

Intchains Group to Present at the Noble Capital Markets Emerging Growth Virtual Equity Conference on June 3-4

Intchains Group to Present at the Noble Capital Markets Emerging Growth Virtual Equity Conference on June 3-4

Intchains Group Limited, a Nasdaq-listed company specializing in altcoin mining and staking, announced its participation in the Noble Capital Markets Emerging Growth Virtual Equity Conference scheduled for June 3-4, 2026. The company will present its business strategy and engage with investors through one-on-one meetings during the virtual event.

Tonix Pharmaceuticals Announces Publication of Phase 1 Clinical Data of TNX-1500, an Fc-Modified anti-CD40L (CD154) Monoclonal Antibody, in the Peer-Reviewed Journal of Clinical Immunology

Tonix Pharmaceuticals Announces Publication of Phase 1 Clinical Data of TNX-1500, an Fc-Modified anti-CD40L (CD154) Monoclonal Antibody, in the Peer-Reviewed Journal of Clinical Immunology

Tonix Pharmaceuticals announced the publication of Phase 1 clinical data for TNX-1500, a novel Fc-modified anti-CD40L monoclonal antibody designed to prevent organ transplant rejection and treat autoimmune diseases. The study demonstrated favorable safety, tolerability, and pharmacodynamics in healthy adults, supporting the planned Phase 2 investig…

Lantronix Announces Preliminary Inclusion in Russell 3000® Index

Lantronix Announces Preliminary Inclusion in Russell 3000® Index

Lantronix Inc., a provider of Edge AI and Industrial IoT solutions, announced its preliminary addition to the Russell 3000 Index as part of the 2026 Russell indexes reconstitution. This inclusion is reflective of the company's strategic repositioning towards higher-growth and higher-value markets and is expected to enhance its visibility to institu…

BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting

BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting

BioCryst Pharmaceuticals announces seven abstracts from its hereditary angioedema (HAE) portfolio to be presented at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting. The data focus on ORLADEYO (berotralstat), the first oral prophylactic therapy for HAE, and navenibart, an investigational monoclonal antibody for attack pr…